Darglitazone (previously known as CP 86325-2) is a member of the thiazolidinedione class of drugs and an agonist of peroxisome proliferator-activated receptor-γ (PPAR-γ), an orphan member of the nuclear receptor superfamily of transcription factors.

It has a variety of insulin-sensitizing effects, such as improving glycemic and lipidemic control, and was researched by Pfizer as a treatment of metabolic disorders such as type 2 diabetes mellitus.

[2] Darglitazone is a thiazolidinedione, which is a class of drugs that can lower blood sugar without increasing insulin production.

Darglitazone can increase the effectiveness of insulin in people with obesity and type 2 diabetes.

Darglitazone is a thiazolidinedione, which is a class of drugs that can lower blood sugar without increasing insulin production.